Surya Singh, M.D.

Vice President and Chief Medical Officer, Specialty Pharmacy, CVS Health
Surya Singh

As Vice President and Chief Medical Officer, Specialty Pharmacy at CVS Health, Surya Singh is responsible for the company’s specialty pharmacy client strategy, analytics, clinical programs and innovation. In this role, he leads a multifunctional team of clinicians and analysts, manages the company’s external partnerships in relevant areas, and participates in a variety of strategic initiatives. Singh is licensed and board certified in internal medicine.

He continues to care for patients as a Hospitalist at the Brigham and Women’s Hospital and is an Adjunct Instructor of Medicine at Harvard Medical School.

Featured Insights by this contributor

Care Management
Oncologists need to take in an enormous amount of information to provide their patients with the most up-to-date treatment. CVS Specialty is partnering with NCCN to provide... More
Briefing
Specialty
Treatment options for hemophilia continue to expand, which is good news for patients. Recently approved therapy options offer better outcomes but need careful management. More
Briefing
Care Management
Cancer therapy is evolving and new treatments are being developed at an almost breakneck pace. To help better manage care and costs for oncology, CVS Health has developed an... More
Briefing
Specialty
CVS Health’s three-tier specialty formulary design separates the increasingly more expensive specialty therapies into three distinct copay or coinsurance categories. Paired with... More
Briefing
Drug Pipeline
When the FDA approves a “supplemental indication” for a drug already on the market — permitting it to be used for new conditions or stages of a disease, or additional patient... More
Briefing
Drug Pipeline
Scientific developments are altering the pace and focus of specialty drug development, while regulatory changes are shortening approval times. This poses new challenges for payors... More
Briefing
Specialty
While the launch time is uncertain, potential PAH generics could give payors greater cost control opportunities for a complex, expensive condition requiring lifelong treatment. More
Briefing
Specialty
Gene therapies bring hope for patients with conditions with few or no treatments, but also other considerations including safety and cost. More
Feature